- MITHRAMYCIN A
-
- $1.00 / 1kg
-
2024-11-19
- CAS:18378-89-7
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 10 mt
- Mithramycin A
-
- $139.00 / 1mg
-
2024-10-28
- CAS:18378-89-7
- Min. Order:
- Purity: 99.28%
- Supply Ability: 10g
- MITHRAMYCIN A
-
- $0.00 / 25KG
-
2023-07-04
- CAS:18378-89-7
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 50000KG/month
|
| | MITHRAMYCIN A Basic information |
| Product Name: | MITHRAMYCIN A | | Synonyms: | AUREOLIC ACID;METHRAMYCIN A;MITHRAMYCIN A, FOR FLUORESCENCE;MITHRAMYCIN A FROM STREPTOMYCES*PLICATUS APPROX. 96;MITHRAMYCIN COMPLEX FROM STREPTOMYCES*PL ICATUS;MITHRAMYCIN FROM STREPTOMYCES PLICATUS;MITHRACIN;MITHRAMYCIN A | | CAS: | 18378-89-7 | | MF: | C52H76O24 | | MW: | 1085.15 | | EINECS: | 634-048-4 | | Product Categories: | antibiotic;Antibiotics;Antitumour | | Mol File: | 18378-89-7.mol |  |
| | MITHRAMYCIN A Chemical Properties |
| Melting point | 180-183 °C | | alpha | D20 -51° (c = 0.4 in ethanol) | | Boiling point | 761.72°C (rough estimate) | | density | 1.1576 (rough estimate) | | refractive index | 1.6500 (estimate) | | storage temp. | 2-8°C | | solubility | Soluble in DMSO (up to 20 mg/ml) or in Ethanol (up to 10 mg/ml) | | form | Powder | | pka | 4.54±0.60(Predicted) | | color | Red to brown | | Merck | 13,7619 | | BRN | 5236667 | | Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 1 month. | | EPA Substance Registry System | Plicamycin (18378-89-7) |
| | MITHRAMYCIN A Usage And Synthesis |
| Description | Mithramycin is an antineoplastic antibiotic produced by
Streptomyces plicatus. It is well known as the aureolic acid
antitumor antibiotic that inhibits both cancer growth and
bone resorption by cross-linking GC-rich DNA, thus
blocking binding of Sp-family transcription factors to
gene regulatory elements. Transcription of c-Src, a gene
implicated in many human cancers and required for
osteoclast-dependent bone resorption, is regulated by the
binding of Sp factors to specific elements in its promoter.
Therefore, this gene represents an important anticancer
target and a potential lead target through which mithramycin
displays action against osteoclastic bone resorption
via an unknown mechanism. Hazards of handling this
drug by the health-care personnel arise from a combination
of factors: (1) its inherent toxicity and (2) the extent
to which workers are exposed to the drug in the course of
carrying out their duties. This exposure may be through
inadvertent ingestion of the drug on foodstuffs (e.g.,
workers’ lunches), inhalation of drug dusts or droplets, or
direct skin contact. Mithramycin has been used to
decrease bone resorption in patients with humoral
hypercalcemia and Paget’s disease. | | Chemical Properties | yellow powder | | Uses | Mithramycin was the first of the aureolic acid class of antitumour antibiotics, isolated from Streptomyces. Mithramycin inhibits transcription and protein synthesis by non-covalent binding with G-C-rich duplex DNA in the presence of magnesium and zinc ions. Mithramycin also induces differentiation of leukemic cells accompanied by an early decrease in c-myc expression, and selectively inhibits collagen-1 gene expression in human fibroblasts. | | Uses | Transcription inhibitor | | Uses | Mithramycin A was the first of the aureolic acid class of antitumor antibiotics, isolated from Streptomyces. Mithramycin inhibits transcription and protein synthesis by non-covalent binding with G-C-rich duplex DNA in the presence of magnesium and zinc ions. Mithramycin also induces differentiation of leukemic cells accompanied by an early decrease in c-myc expression, and selectively inhibits collagen-1 gene expression in human fibroblasts. | | Indications | Plicamycin (mithramycin, Mithracin) is one of the chromomycin
group of antibiotics produced by Streptomyces
tanashiensis. Plicamycin binds to DNA and inhibits transcription.
It also inhibits resorption of bone by osteoblasts,
thus lowering serum calcium levels.Very little is
known about its distribution, metabolism, and excretion.
Because of its severe toxicity, plicamycin has limited clinical
utility.The major indication for plicamycin therapy is
in the treatment of life-threatening hypercalcemia associated
with malignancy. Plicamycin also can be used in
the palliative therapy of metastatic testicular carcinoma
when all other known active drugs have failed. | | Definition | ChEBI: Mithramycin is a carbohydrate-containing antibiotic, an anthracycline antibiotic, an aureolic acid and a secondary alpha-hydroxy ketone. It has a role as an antineoplastic agent, an EC 2.7.7.6 (RNA polymerase) inhibitor and a metabolite. | | Application | Mithramycin, recently renamed plicamycin, was found in the culture broth of Streptomyces argillaceus and S. tanashiensis by Abbott Laboratories in 1952. It is structurally related to chromomycin A3. Mithramycin shows strong inhibitory activity against malignant cells of human origin. It acts by inhibition of the DNA-directed RNA synthesis through binding with DNA. Mithramycin is used intravenously to treat cancers of the embryonal cells, seminoma, choriocarcinoma, etc. | | Brand name | Mithracin (Pfizer) [Name
previously used: Mithramycin.]. | | General Description | Chemical structure: aureolic acid | | Biological Activity | Anticancer antibiotic that selectively binds to G-C-rich DNA in the presence of Mg 2+ or Zn 2+ , inhibiting RNA and DNA polymerase action. Inhibits c-myc expression and induces myeloid differentiation of HL-60 promyelocytic leukemia cells. | | Biochem/physiol Actions | Anticancer antibiotic. Inhibits transcription and protein synthesis. Binds to DNA in native chromatin. Substrate of Pgp in MDR phenotypes. | | storage | Store at -20°C | | Purification Methods | Purify mithramycin A by crystallisation from CHCl3. It is soluble in MeOH, EtOH, Me2CO, EtOAc, Me2SO and H2O, and moderately soluble in CHCl3, but is slightly soluble in *C6H6 and Et2O. It is a fluorescent antitumour agent used in flow cytometry. [Thiem & Meyer Tetrahedron 37 551 1981, NMR: Yu et al. Nature 218 193 1968, Beilstein 17/1 V 672.] | | Toxicity evaluation | Mithramycin inhibits mRNA and protein synthesis by adhering
to DNA. Mithramycin appears to affect bone resorption by
stimulating osteoclast activity and results in hypocalcemia and
hypophosphatemia. It is believed to lower serum calcium
concentrations, but the exact mechanism is unknown. It may
act by blocking hypercalcemic action of vitamin D or by
inhibiting the effect of parathyroid hormone on osteoclasts. Its
inhibition of DNA-dependent RNA synthesis appears to render
osteoclasts unable to fully respond to parathyroid hormone
with the biosynthesis necessary for osteolysis. | | References | 1) Lin?et al. (2007),?Mithramycin A inhibits DNA methyltransferase and metastasis potential of lung cancer cells; Anticancer Drugs,?18?1157
2) Jia?et al.?(2010),?Combined treatment of pancreatic cancer cells with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic anti-tumor activity; Cancer Res.,?70?1111
3) Lee?et al. (2006),?Mithramycin A sensitizes cancer cells to TRAIL-mediated apoptosis by down-regulation of XIAP gene promoter through Sp1 sites; Mol. Cancer Ther.,?5?2737 |
| | MITHRAMYCIN A Preparation Products And Raw materials |
|